Recent Company News

• 06:34 AM ET Aug 11, 2026
  

  Energy, tech and healthcare the top gainers; insurance, food/beverage and travel the main laggards:

• 02:59 AM ET Jul 23, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:01 AM ET Aug 11, 2026
  

  Galderma receives EU approval for Restylane Shaype (CHF 175.95, 0.00)

• 04:42 AM ET Jul 30, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 03:14 AM ET Jul 30, 2026
  

  Galderma Group upgraded to overweight from equal-weight at Morgan Stanley (pre-European open) (CHF 180.35, +3.25)

• 09:19 AM ET Jul 23, 2026
  

  Transcript Intelligence: Galderma Group Q2 Earnings Guidance

• 09:19 AM ET Jul 23, 2026
  

  Transcript Intelligence: Galderma Group Q2 Earnings Themes

• 09:19 AM ET Jul 23, 2026
  

  Transcript Intelligence: Galderma Group Q2 Earnings Q&A

• 01:13 AM ET Jul 23, 2026
  

  Galderma Group reports H1 core EPS $2.34 vs FactSet $2.25 [4 est, $2.09-2.48]; raises FY net sales growth to +19-21% at constant currency vs prior guidance +17-20% (CHF 174.05, 0.00)